2.Uyeki, TM, Mehta, AK, Davey, RT, Jr, et al.Clinical management of Ebola virus disease in the United States and Europe. N Engl J Med 2016;374:636–646.
4.Kraft, CS, Hewlett, AL, Koepsell, S, et al.The use of TKM-100802 and convalescent plasma in 2 patients with Ebola virus disease in the United States. Clin Infect Dis 2015;61:496–502.
5.Liddell, AM, Davey, RT Jr, Mehta, AK, et al.Characteristics and clinical management of a cluster of 3 patients with Ebola virus disease, including the first domestically acquired cases in the United States. Ann Intern Med 2015;163:81–90.
6.Lyon, GM, Mehta, AK, Varkey, JB, Brantly, K, Plyler, L, McElroy, AK, et al.Clinical care of two patients with Ebola virus disease in the United States. N Engl J Med 2014;371:2402–2409.
7.Raabe, VN, Kann, G, Ribner, BS, et al.Favipiravir and ribavirin treatment of epidemiologically linked cases of Lassa fever. Clin Infect Dis 2017;65:855–859.
8.Beeching, NJ, Fenech, M, Houlihan, CF.Ebola virus disease, 2014. BMJ 2014;349:g7348.
9.Lowe, JJ, Olinger, PL, Gibbs, SG, et al.Environmental infection control considerations for Ebola. Am J Infect Control 2015;43:747–749.
10.Bausch, DG, Towner, JS, Dowell, SF, et al.Assessment of the risk of Ebola virus transmission from bodily fluids and fomites. J Infect Dis 2007;196 suppl 2:S142–S147.
11.Clark, DV, Kibuuka, H, Millard, M, Wakabi, S, Lukwago, L, Taylor, A, et al.Long-term sequelae after Ebola virus disease in Bundibugyo, Uganda: a retrospective cohort study. Lancet Infect Dis 2015;15:905–912.
12.Bellan, SE, Pulliam, JR, Dushoff, J, Meyers, LA.Ebola control: effect of asymptomatic infection and acquired immunity. Lancet 2014;384:1499–1500.
13.Richardson, ET, Kelly, JD, Barrie, MB, et al.Minimally symptomatic infection in an Ebola ‘hotspot’: a cross-sectional serosurvey. PLoS Negl Trop Dis 2016;10(11):e0005087.
14.Mulangu, S, Alfonso, VH, Hoff, NA, et al.Serologic evidence of Ebolavirus infection in a population with no history of outbreaks in the Democratic Republic of the Congo. J Infect Dis 2018;217:529–537.
15.Hewlett, AL, Varkey, JB, Smith, PW, Ribner, BS.Ebola virus disease: preparedness and infection control lessons learned from two biocontainment units. Curr Opin Infect Dis 2015;28:343–348.
16.Isakov, A, Jamison, A, Miles, W, Ribner, B.Safe management of patients with serious communicable diseases: recent experience with Ebola virus. Ann Intern Med 2014;161:829–830.
17.Lai, L, Davey, R, Beck, A, Xu, Y, Suffredini, AF, Palmore, T, et al.Emergency postexposure vaccination with vesicular stomatitis virus-vectored Ebola vaccine after needlestick. JAMA 2015;313:1249–1255.
18.Jacobs, M, Aarons, E, Bhagani, S, et al.Postexposure prophylaxis against Ebola virus disease with experimental antiviral agents: a case series of healthcare workers. Lancet Infect Dis 2015;15:1300–1304.
19.Ledgerwood, JE, DeZure, AD, Stanley, DA, et al.Chimpanzee adenovirus vector Ebola vaccine. N Engl J Med 2017;376:928–938.
20.Houlihan, CF, McGowan, CR, Dicks, S, et al. Ebola exposure, illness experience, and Ebola antibody prevalence in international responders to the West African Ebola epidemic 2014–2016: a cross-sectional study. PLoS Med 2017;14(5):e1002300.
21.Parham, M, Edison, L, Soetebier, K, et al.Ebola active monitoring system for travelers returning from West Africa to Georgia, 2014–2015. Morb Mortal Wkly Rep 2015;64:347–350.
22.Smith, MW, Smith, PW, Kratochvil, CJ, Schwedhelm, S.The psychosocial challenges of caring for patients with Ebola virus disease. Health Secur 2017;15:104–109.